Council of Scientific and Industrial Research (CSIR) through its New Millennium Indian Technology Leadership Initiative (NMITLI) program has approved a project for the development of human monoclonal antibodies (hmAbs) that can neutralize SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in patients.
Implemented by collaboration of institutes; BBIL to lead
It will be implemented through a collaboration ofNational Centre for Cell Science (NCCS) Pune; Indian Institute of Technology(IIT),Indore;PredOmixTechnologies Ltd,Gurugram;and Bharat Biotech International Ltd (BBIL),Hyderabad.
- The project will be led by Vaccines and biotherapeutics maker BBIL.
- It will also be the commercial partner and responsible for subsequent development and commercialization of the hmAbs generated.
- It should be noted that recently,Indian Council of Medical Research (ICMR) has also partnered with BBIL to develop a fully indigenous vaccine for Covid-19.
About hmAbs:
Monoclonal antibody therapy is a form of immunotherapy designed to produce immunity to a disease or to enhance resistance by the immune system. This new project aims to generate hmAbsto SARS-CoV-2 from the gradual recovery phase of COVID-19 patients and select high affinity and neutralizing antibodies.
- The project also generateshmAbs clones that can neutralize the mutated virus so that it could be readily used for combating future SARS-CoV infections.
About NMITLI:
NMITLI is a flagship program of CSIR aimed to support new ideas and projects from academic institutions and industries.
About CSIR:
Works under– Ministry of Science & Technology
Director General– Dr. Shekhar C. Mande
About BBIL:
Found & Chairman and Managing Director (CMD)– Dr. Krishna M. Ella
Headquarter– Hyderabad, Telangana
